Posted on 02/06/2009 in Pharmaceutical Company Product News GlaxoSmithKline (GSK) is determined to discover new drugs that will be beneficial to patients, it has stated.
Phase III clinical trials of the company's drug pazopanib showed it could reduce the risk of tumour progression or death by 54 per cent compared to a placebo.
Although there have been many medical advances, there is still a need for effective and well-tolerated treatments for patients with advanced kidney cancer, noted Dr Cora N Sternberg from the San Camillo and Forlanini hospitals.
Regardless of whether the sufferer had received previous therapy, they showed significant improvement after taking the medication in the clinical trials and without any serious side effects, she further commented.
Senior vice-president of GSK's oncology research and development unit Paolo Paoletti asserted the global studies are designed to find new ways of tackling a diverse group of cancers.
"We're extremely pleased to see the progress in developing pazopanib for advanced kidney cancer, but this represents just one type of cancer in need of new treatments," he said.
Last month, the company discussed the results of three studies for the cervical cancer vaccine Cervarix, proving it can generate a higher immune response than Gardasil.Other news stories from 02/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
